Mrs Sophie Binay and Mr Yannick Pletan will continue to assume their current functions in the company as CSO and CMO respectively.
Mr Alain Munoz, MD, PhD, new chairman of the Acticor board of directors, is a physician, qualified in cardiology and intensive care.
He has over 30 years of experience in the industry at senior management level. He served as SVP for international development in the Sanofi Group and in the pharmaceutical division of Fournier Laboratories.
He has been a member of the Scientific Committee of the French drug agency, chairman of the board of Hybrigenics SA and Novagali Pharma SA (TODAY SANTEN).
He presently serves on the scientific advisory board of Valneva SA and in is an independent board member of Amryt Pharma plc, Auris Medical Holding AG and Zealand Pharma A/S.
Sophie Binay, PhD, nominated as general manager and CSO of Acticor Biotech, has over 20 years' experience in start-ups and mid-size companies within the biotechnology areas.
She has expertise in oncology, immunology and virology. Sophie has managed numbers of innovative R and D projects from the proof-of-concept to early clinical development.
In her previous positions, Sophie was vice-president Research and Early Clinical Development at PEP-Therapy, responsible for nonclinical R and D activities at InnaVirVax, Head of translational programs in oncology at Gustave Roussy Cancer Center and R and D director at Onxeo (former Bioalliance Pharma).
Yannick is an expert in clinical development within the pharmaceutical industry. He previously held leadership positions at Roche, Pfizer, Sanofi and Pierre Fabre.
Before joining Acticor Biotech, he served as head of the Medical Division and was a board member of the Foundation at Roche France and member of the Global Medical Affairs Committee at Hoffman La Roche Ltd (Switzerland).
Prior to these activities, he was also vice-president, head of Medical and Scientific Division and board member of the Foundation at Pfizer (NYSE: PFE).
Acticor is developing glenzocimab (ACT017), a humanized Antibody Fragment. The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI, and inhibits its action. Evidence of antithrombotic efficacy of glenzocimab and safety of inhibition of GPVI have been established both ex vivo and in vivo.
The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer